IMVT
Immunovant·NASDAQ
--
--(--)
--
--(--)
4.98 / 10
Netural
Analyst sentiment is mixed but leaning positive: 50% Buy and 50% Neutral ratings from two institutions, with a historical weighted rating of 2.21. Fund-flow data show a good score of 7.75/10, though overall and block trends are negative—suggesting incremental buying despite macro-level caution. Together, the analyst and fund-flow picture indicates constructive participation but no overwhelming conviction, aligning with the stock's neutral overall rating.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-06
InstitutionWolfe Research
Times predicted1
Historical Win Rate100.0%
Is money flowing into or out of IMVT?
- IMVT holds a Bearish analyst rating, with 50% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.98/10 (Netural).
